BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MIGENIX Inc. Completes Name Change With New Trading Symbol: MGI


10/19/2005 5:11:32 PM

VANCOUVER, BC and SAN DIEGO, CA, Sept. 21 /PRNewswire-FirstCall/ -- MIGENIX Inc. (formerly Micrologix Biotech Inc.) (TSX: MGI; OTC: MGIFF), a developer of drugs for infectious and degenerative diseases, will start trading on the TSX under the symbol "MGI" effective at the open on September 21, 2004. This change in trading symbol reflects the name change that was effective September 9, 2004. Trading on the US OTC market will be under the symbol "MGIFF" (formerly "MGIXF").

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs for the prevention and treatment of major medical diseases and certain conditions with unmet medical need. With its expertise and experience in product development, the Company is focused on advancing its clinical and preclinical stage pipeline of product candidates in the areas of infectious and degenerative diseases. MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.mbiotech.com/.

"Jim DeMesa" ----------------------- James DeMesa, M.D., MBA President & CEO Contacts: Jonathan Burke MIGENIX Inc. Tel: (604) 221-9666 Extension 241 jburke@mbiotech.com Gino de Jesus or Dian Griesel, Ph.D. The Investor Relations Group Tel: (212) 825-3210 Theproteam@aol.com

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

MIGENIX Inc.

CONTACT: Jonathan Burke, MIGENIX Inc., Tel: (604) 221-9666 Extension241, jburke@mbiotech.com; Gino de Jesus or Dian Griesel, Ph.D., TheInvestor Relations Group, Tel: (212) 825-3210, Theproteam@aol.com;To request a free copy of this organization's annual report, please go tohttp://www.newswire.ca/ and click on reports@cnw.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES